The approval of Cabenuva was based on data from two phase 3 trials which included 1182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) prior to initiation. The ...
Simultaneous approval of VOCABRIA (cabotegravir oral tablets), for short-term treatment in conjunction with CABENUVA (cabotegravir and rilpivirine extended-release injectable suspensions), also ...
People with HIV may have to take multiple medicines just to keep the virus under control. Medicines for HIV are usually taken every day, and it is crucial that people do not miss their dose or else ...
(Reuters) - The U.S. Food and Drug Administration on Thursday approved a long-acting HIV injection from British drugmaker GlaxoSmithKline's HIV treatment division, ViiV Healthcare. "This is the first ...
A GSK logo is seen at the GSK research centre in Stevenage (Reuters) - GlaxoSmithKline's HIV treatments division has received approval for its long-acting HIV injection from Canada's healthcare ...
Despite high hopes for its game-changing monthly HIV regimen Cabenuva, GlaxoSmithKline's ViiV Healthcare went back to the drawing board after the FDA slammed the drug's manufacturing late last year.
Last week, the FDA denied the approval of Cabenuva, the first of its kind monthly HIV injection treatment. Developers hoped that the monthly injection would replace daily pills, thus making life ...
TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that a supplemental New Drug Application (sNDA) has been submitted to the U.S.
After the FDA rejected its once-monthly HIV injection Cabenuva in December, GlaxoSmithKline’s keeping the talk going about its long-acting options. Now, it has rolled out detailed data showing a ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Aside from a daily ...
(Reuters) - GlaxoSmithKline's HIV treatments division has received approval for its long-acting HIV injection from Canada's healthcare regulator, in a major win for the British drugmaker after a U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback